The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Targeted Migration of Mesenchymal Stem Cells Modified With CXCR4 Gene to Infarcted Myocardium Improves Cardiac Performance
Open accessAbstract
With the goal of devising a non-invasive cell therapy for cardiac repair that may be well tolerated by patients with myocardial infarction (MI), this study evaluated the efficacy of intravenous infusion of genetically modified mesenchymal stem cells (MSCs) overexpressing CXC chemokine receptor 4 (CXCR4). CXCR4 is the cognate receptor for stromal-derived factor-1 (SDF-1), a chemokine required for homing of progenitor cells to ischemic tissues. In this study, retrovirally transduced MSCs constitutively expressing CXCR4 (CXCR4-MSCs) were delivered intravenously 24 hours after coronary occlusion/reperfusion in rats. When compared with untransduced MSCs, CXCR4-MSCs homed in toward the infarct region of the myocardium in greater numbers. In the CXCR4-MSC-treated animals, echocardiographic imaging 30 days after MI showed a decrease in anterior wall thinning and good preservation of left ventricular (LV) chamber dimensions, whereas the animals treated with saline or unmodified MSCs showed significant remodeling. Histochemical analysis showed a decrease in collagen I/III ratio in the infarcted wall of CXCR4-MSC-treated animals, thereby suggesting improved chamber compliance. Assessment revealed post-MI recovery of LV function in the CXCR4-MSC-treated animals, whereas LV function remained depressed in the saline and MSC-treated animals. In summary, intravenous delivery of genetically modified MSCs expressing CXCR4 may be a useful, non-invasive, and safe therapeutic strategy for post-infarction myocardial repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow
Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. (2002) · Nature · doi:10.1038/nature00870 · Cited by 5,518
RetractedMultilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart
Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J., & Kessler, P. D. (2002) · Circulation · doi:10.1161/hc0102.101442 · Cited by 2,234
Cardiomyocytes can be generated from marrow stromal cells in vitro
Makino, S., Fukuda, K., Miyoshi, S., Konishi, F., Kodama, H., Pan, J., Sano, M., Takahashi, T., Hori, S., Abe, H., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5298 · Cited by 1,884
Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4
Peled, A., Petit, I., Kollet, O., Magid, M., Ponomaryov, T., Byk, T., Nagler, A., Ben-Hur, H., Many, A., Shultz, L., et al. (1999) · Science · doi:10.1126/science.283.5403.845 · Cited by 1,644
Mangi, A. A., Noiseux, N., Kong, D., He, H., Rezvani, M., Ingwall, J. S., & Dzau, V. J. (2003) · Nature Medicine · doi:10.1038/nm912 · Cited by 1,509
Self-citationKinnaird, T., Stabile, E., Burnett, M. S., Lee, C. W., Barr, S., Fuchs, S., & Epstein, S. E. (2004) · Circulation Research · doi:10.1161/01.res.0000118601.37875.ac · Cited by 1,415
Kinnaird, T., Stabile, E., Burnett, M. S., Shou, M., Lee, C. W., Barr, S., Fuchs, S., & Epstein, S. E. (2004) · Circulation · doi:10.1161/01.cir.0000124062.31102.57 · Cited by 1,305
Askari, A. T., Unzek, S., Popovic, Z. B., Goldman, C. K., Forudi, F., Kiedrowski, M., Rovner, A., Ellis, S. G., Thomas, J. D., DiCorleto, P. E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14232-8 · Cited by 1,270
Cited by
Mesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445
Mesenchymal Stem Cell Migration and Tissue Repair
Fu, X., Liu, G., Halim, A., Ju, Y., Luo, Q., & Song, G. (2019) · Cells · doi:10.3390/cells8080784 · Cited by 1,044
Mesenchymal stem cells: a new trend for cell therapy
Wei, X., Yang, X., Han, Z.-P., Qu, F.-F., Shao, L., & Shi, Y.-F. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.50 · Cited by 942
Regenerative medicine: Current therapies and future directions
Mao, A. S., & Mooney, D. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508520112 · Cited by 941
Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease
Ranganath, S. H., Levy, O., Inamdar, M. S., & Karp, J. M. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.02.005 · Cited by 809
Shattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair
Shi, Y., Hu, G., Su, J., Li, W., Chen, Q., Shou, P., Xu, C., Chen, X., Huang, Y., Zhu, Z., et al. (2010) · Cell Research · doi:10.1038/cr.2010.44 · Cited by 575
Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement
Ullah, M., Liu, D. D., & Thakor, A. S. (2019) · iScience · doi:10.1016/j.isci.2019.05.004 · Cited by 549
In situ-forming injectable hydrogels for regenerative medicine
Yang, J.-A., Yeom, J., Hwang, B. W., Hoffman, A. S., & Hahn, S. K. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.07.006 · Cited by 532
Regenerative Effects of Transplanted Mesenchymal Stem Cells in Fracture Healing
Granero-Moltó, F., Weis, J. A., Miga, M. I., Landis, B., Myers, T. J., O'Rear, L., Longobardi, L., Jansen, E. D., Mortlock, D. P., & Spagnoli, A. (2009) · Stem Cells · doi:10.1002/stem.103 · Cited by 530
Paracrine mechanisms of stem cell reparative and regenerative actions in the heart
Mirotsou, M., Jayawardena, T. M., Schmeckpeper, J., Gnecchi, M., & Dzau, V. J. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.08.005 · Cited by 486
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M., & Veiseh, O. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 439
MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation
Kean, T. J., Lin, P., Caplan, A. I., & Dennis, J. E. (2013) · Stem Cells International · doi:10.1155/2013/732742 · Cited by 433
Mesenchymal Stem Cells Migration Homing and Tracking
Sohni, A., & Verfaillie, C. M. (2013) · Stem Cells International · doi:10.1155/2013/130763 · Cited by 424
Concise Review: Mesenchymal Stem Cells and Translational Medicine: Emerging Issues
Ren, G., Chen, X., Dong, F., Li, W., Ren, X., Zhang, Y., & Shi, Y. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2011-0019 · Cited by 307
Self-citationMesenchymal stem cell-based drug delivery strategy: from cells to biomimetic
Wu, H.-H., Zhou, Y., Tabata, Y., & Gao, J.-Q. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.019 · Cited by 288
Enhancing the Migration Ability of Mesenchymal Stromal Cells by Targeting the SDF-1/CXCR4 Axis
Marquez-Curtis, L. A., & Janowska-Wieczorek, A. (2013) · BioMed Research International · doi:10.1155/2013/561098 · Cited by 287
Baldari, S., Di Rocco, G., Piccoli, M., Pozzobon, M., Muraca, M., & Toietta, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102087 · Cited by 279
Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine
Lau, T. T., & Wang, D.-A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.546338 · Cited by 270
Liu, H., Liu, S., Li, Y., Wang, X., Xue, W., Ge, G., & Luo, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034608 · Cited by 262
Self-citationMesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine
Satija, N. K., Singh, V. K., Verma, Y. K., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, R. P., & Gurudutta, G. U. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00857.x · Cited by 252
Stem cell homing in musculoskeletal injury
Fong, E. L. S., Chan, C. K., & Goodman, S. B. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.101 · Cited by 212
“In another study which evaluated the intravenous infusion of genetically modified MSC over-expressing CXCR4 after coronary occlusion/reperfusion in rats, CXCR4-MSC was observed to home towards the infarct region of themyocardium in greater numbers as compared to untransducedMSC [63].”
Kwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208
Genetic Engineering of Mesenchymal Stem Cells and Its Application in Human Disease Therapy
Hodgkinson, C. P., Gomez, J. A., Mirotsou, M., & Dzau, V. J. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.165 · Cited by 150
Stem cells as vectors for antitumour therapy
Loebinger, M. R., & Janes, S. M. (2010) · Thorax · doi:10.1136/thx.2009.128025 · Cited by 109
Metadata
- Authors
- Cheng, Z., Ou, L., Zhou, X., Li, F., Jia, X., Zhang, Y., Liu, X., Li, Y., Ward, C. A., Melo, L. G., & Kong, D.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 16
- Issue
- 3
- Pages
- 571-579
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2002868143
- Cited by
- 440
- References
- 43
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.